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 Purpose: To determine the performance of positron emission mammography 
(PEM), as compared with magnetic resonance (MR) imaging, including 
the effect on surgical management, in ipsilateral breasts with cancer.
 Materials and 
Methods: 
Four hundred seventy-two women with newly diagnosed breast 
cancer who were offered breast-conserving surgery consented from 
September 2006 to November 2008 to participate in a multicenter 
institutional review board–approved, HIPAA-compliant protocol. Par-
ticipants underwent contrast material–enhanced MR imaging and 
fl uorine 18 fl uorodeoxyglucose PEM in randomized order; resultant 
images were interpreted independently. Added biopsies and changes 
in surgical procedure for the ipsilateral breast were correlated with 
histopathologic fi ndings. Performance characteristics were compared 
by using the McNemar test and generalized estimating equations.
 Results: Three hundred eighty-eight women (median age, 58 years; age range, 
26–93 years; median estimated tumor size, 1.5 cm) completed the 
study. Additional cancers were found in 82 (21%) women (82 ip-
silateral breasts; median tumor size, 0.7 cm). Twenty-eight (34%) 
of the 82 breasts were identifi ed with both PEM and MR imaging; 
21 (26%) breasts, with MR imaging only; 14 (17%) breasts, with 
PEM only; and seven (8.5%) breasts, with mammography and ultra-
sonography. Twelve (15%) cases of additional cancer were missed 
at all imaging examinations. Integration of PEM and MR imaging in-
creased cancer detection—to 61 (74%) of 82 breasts versus 49 (60%) 
of 82 breasts identifi ed with MR imaging alone ( P  , .001). Of 306 
breasts without additional cancer, 279 (91.2%) were correctly as-
sessed with PEM compared with 264 (86.3%) that were correctly 
assessed with MR imaging ( P = .03). The positive predictive value of 
biopsy prompted by PEM fi ndings (47 [66%] of 71 cases) was higher 
than that of biopsy prompted by MR fi ndings (61 [53%] of 116 cases) 
( P = .016). Of 116 additional cancers, 61 (53%) were depicted 
by MR imaging and 47 (41%) were depicted by PEM ( P = .043). 
Fifty-six (14%) of the 388 women required mastectomy: 40 (71%) of 
these women were identifi ed with MR imaging, and 20 (36%) were 
identifi ed with PEM ( P  , .001). Eleven (2.8%) women underwent 
unnecessary mastectomy, which was prompted by only MR fi ndings 
in fi ve women, by only PEM fi ndings in one, and by PEM and MR 
fi ndings in fi ve. Thirty-three (8.5%) women required wider excision: 
24 (73%) of these women were identifi ed with MR imaging, and 
22 (67%) were identifi ed with PEM.
 Conclusion: PEM and MR imaging had comparable breast-level sensitivity, although 
MR imaging had greater lesion-level sensitivity and more accurately 
depicted the need for mastectomy. PEM had greater specifi city at the 
breast and lesion levels. Eighty-nine (23%) participants required more 
extensive surgery: 61 (69%) of these women were identifi ed with MR 
imaging, and 41 (46%) were identifi ed with PEM ( P = .003). Fourteen 
(3.6%) women had tumors seen only at PEM.
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Supplemental material:  http://radiology.rsna.org/lookup/suppl
/doi:10.1148/radiol.10100454/-/DC1 
 1 From American Radiology Services, Johns Hopkins Green 
Spring, Lutherville, Md (W.A.B.); Certus International, St 
Louis, Mo (K.S.M., J.P.M.); Boca Raton Community Hospital, 
Boca Raton, Fla (K.S.); Scripps Clinic, Scripps Green Hos-
pital, La Jolla, Calif (M.T.); Department of Radiology, Uni-
versity of North Carolina, Chapel Hill, NC (E.D.P.); University 
of Southern California, Norris Cancer Center, Los Angeles, 
Calif (L.H.L.); Naviscan, San Diego, Calif (D.N., J.E.K.); and 
Department of Biostatistics, Boston University School of 
Public Health, Boston, Mass (A.O.). Received February 27, 
2010; revision requested April 5; revision received May 20; 
accepted June 9; fi nal version accepted July 7. Supported 
by Naviscan and the National Institutes of Health. 
 Address correspondence to W.A.B., 
e-mail:  wendieberg@gmail.com . 
 Current addresses: 
 2 American College of Radiology Imaging Network, 
Lutherville, Md. 
 3 Department of Radiology, Medical University of South 
Carolina, Charleston, SC. 
 4 National Cancer Institute, Bethesda, Md. 
 5 Clinical Research Program, Children’s Hospital, 
Boston, Mass. 
 q RSNA, 2010 
60 radiology.rsna.org n Radiology: Volume 258: Number 1—January 2011
 BREAST IMAGING: Positron Emission Mammography vs MR Imaging of Presurgical Ipsilateral Breast Berg et al
 Dedicated high-spatial-resolution pos-
itron emission mammography (PEM—
ie, positron emission tomography with 
detectors specialized for imaging the 
breast) with fl uorine 18 fl uorodeoxy-
glucose (FDG) has been shown to have 
a high PPV of 0.88 and to depict breast 
malignancies not seen on mammograms 
and/or US images with overall sensitivity 
of 90% ( 11 ). As such, PEM appears to 
be more specifi c and possibly more ac-
curate than MR imaging, although to our 
knowledge, a direct comparison has not 
been performed previously. The pur-
pose of this study was to determine the 
performance characteristics of PEM, as 
compared with MR imaging, including 
the effect on surgical management, in 
ipsilateral breasts with cancer. 
 Materials and Methods 
 This study was funded in part by Navi-
scan (San Diego, Calif), the manu-
facturer of the PEM device described 
herein. All PEM examinations were 
provided free of charge to participants. 
One author (W.A.B.) is a consultant for 
Naviscan, with compensation based on 
the fair-market value time spent and not 
tumor remaining in the breast. Such re-
sidual tumor may increase the risk of local 
recurrence, although this risk is markedly 
decreased when radiation therapy and/or 
systemic therapy is administered. 
 It is desirable to accurately map the 
extent of the tumor before administering 
treatment to facilitate optimal decision 
making for the patient and the treat-
ing physicians. This may be especially 
important in young women, in women 
with dense breasts, in women with inva-
sive lobular histologic fi ndings, or when 
an extensive intraductal component is 
present, as residual mammographically 
occult tumor is more common in these 
situations ( 2,5,6 ). Assessing neoadju-
vant treatment response also depends 
on accurate measurements of tumor size 
prior to and following treatment; mag-
netic resonance (MR) imaging has been 
shown to be more effective than mam-
mography or clinical examination in this 
setting ( 7,8 ), and tumor size is more 
accurately depicted by MR imaging than 
by US ( 9 ). In a meta-analysis, preop-
erative contrast material–enhanced MR 
imaging was shown to depict additional 
ipsilateral disease in 16% of women 
with breast cancer ( 5 ). It is not clear, 
however, whether this examination re-
sults in improved patient outcomes. 
Approximately 1% of women undergo 
unnecessary mastectomy as a result of 
preoperative MR fi ndings ( 5 ), although 
MR imaging–prompted biopsy has high 
positive predictive value (PPV), with a 
median PPV of 0.69 across 19 series 
( 5 ). In a single-institution series, MR 
imaging was believed to have delayed 
defi nitive surgery for an average of 
22 days owing to additional prompted 
biopsies ( 10 ). 
 When patients are appropriately selected, breast-conserving sur-gery (BCS) followed by radia-
tion (ie, breast conservation therapy) is 
widely accepted as producing equivalent 
survival compared with mastectomy in 
women with newly diagnosed cancer 
( 1 ). Breast conservation therapy is con-
sidered desirable when a cosmetically 
acceptable result can be achieved by 
means of complete removal of both the 
tumor and clear margins of excision. 
The size and extent of breast cancer 
are frequently underestimated on the 
basis of clinical examination and mam-
mographic fi ndings, with or without sup-
plemental ultrasonography (US) ( 2–4 ). 
When the cancer size is underestimated 
and the patient has chosen breast con-
servation therapy, initial surgical margins 
may be positive for malignancy, requir-
ing reexcision or mastectomy. When the 
focality of the tumor is underestimated, 
the margins may be clear, with residual 
 Implications for Patient Care 
 PEM is an alternative for women  n
who cannot tolerate MR imaging. 
 PEM has improved specifi city  n
compared with MR imaging and 
is therefore less likely to prompt 
unnecessary biopsies. 
 Review of mammograms together  n
with MR or PEM images, or 
both, improves the detection of 
additional disease. 
 Advances in Knowledge 
 Positron emission mammography  n
(PEM) proved to be complemen-
tary to MR imaging in defi ning 
the preoperative disease extent 
in the ipsilateral breasts of 
women with newly diagnosed 
breast cancer. 
 Of 388 participants anticipating  n
breast-conserving surgery, 82 
(21%) were ultimately found to 
have additional tumor foci after 
all imaging examinations and sur-
gery: 49 (13%) participants had 
additional disease depicted at 
MR imaging, 42 (11%) had addi-
tional disease depicted at PEM, 
and 70 (18%) were identifi ed 
after review of combined conven-
tional (mammographic and ultra-
sonographic), PEM, and MR 
images. 
 Combined conventional imaging  n
and PEM depicted additional dis-
ease in 53 (14%) participants—
not signifi cantly different from 
the detection achieved with 
review of combined conventional 
and MR images (in 59 [15%] 
participants) ( P = .26). 




 BCS = breast-conserving surgery 
 BI-RADS = Breast Imaging Reporting and Data System 
 CI = confi dence interval 
 DCIS = ductal carcinoma in situ 
 FDG = fl uorine 18 fl uorodeoxyglucose 
 IDC = invasive ductal carcinoma 
 PEM = positron emission mammography 
 PPV = positive predictive value 
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After all surgeries, the site investiga-
tors documented whether mastectomy 
had been performed and whether the 
mastectomy had been appropriate or 
inappropriate (ie, lumpectomy would 
have suffi ced) on the basis of the true 
disease extent. If the mastectomy was 
inappropriate, the investigators detailed 
whether the procedure was prompted 
by imaging fi ndings—and, if so, by which 
imaging study—or by the patient’s prefer-
ence. Investigators were asked whether 
the surgical management planned after 
conventional imaging had been modifi ed 
(to wider local excision, mastectomy, or 
excision of a high-risk lesion) owing to 
PEM or MR fi ndings and whether or 
not this had proved to be appropriate. 
Finally, estimates of disease extent on 
each PEM and MR imaging study were 
rated as accurate, underestimated, or 
overestimated (by 2 cm or more in size 
and/or additional foci). For this analy-
sis, a suspicious lesion that underwent 
biopsy after study entry and was found 
to be benign preoperatively was included 
as an overestimation. 
 Analysis 
 Only those lesions that did not undergo 
biopsy prior to study entry were con-
sidered in the analysis, with a separate 
review of index cancer detection. Le-
sions assigned a Breast Imaging Re-
porting and Data System (BI-RADS) 
score of 4a or higher or 3 with a recom-
mendation for biopsy were considered 
to be positive for cancer at imaging (ie, 
imaging positive). Since PEM and MR 
imaging were performed as diagnos-
tic examinations, lesions assigned a 
BI-RADS assessment 3 or lower with 
recommendation for additional imaging 
or for short-term or routine follow-up 
were considered imaging negative. Posi-
tive truth was defi ned as a diagnosis of 
malignancy within 1 year on the basis 
of the most severe histopathologic re-
sult for that lesion. High-risk lesions 
detected at core-needle biopsy (atypi-
cal ductal hyperplasia, atypical lobular 
hyperplasia, lobular carcinoma in situ, 
columnar cell change with atypia, radial 
sclerosing lesion, atypical papilloma) 
were excised, as were lesions show-
ing benign papilloma in the core-needle 
 Imaging 
 PEM and MR imaging examinations 
were performed after study enrollment 
in randomized order, within 5 business 
days of each other, without regard to 
timing in the menstrual cycle. Enrolled 
participants had to agree to undergo any 
recommended biopsies and/or follow-up 
imaging, even if they were considering 
mastectomy. Additional biopsies could 
not be performed during the interval be-
tween MR imaging and PEM. 
 Data Collection 
 The fi ndings of conventional imaging 
(mammography and often targeted US) 
performed prior to study entry were re-
viewed with the histopathology results. 
Independent interpretations of MR and 
PEM images were performed by differ-
ent investigators who were blinded to 
the results of the other examination. 
There were exceptions to this blinding: 
In 20 cases, the same investigator inter-
preted both PEM and MR imaging ex-
aminations because clinical care would 
have otherwise been delayed (with ran-
domization order followed for interpre-
tation); in another nine cases, the in-
terpreting investigator referred to the 
MR image results while interpreting the 
PEM study; and in two cases in which 
the interpreting investigator referred 
to the PEM study while interpreting 
the MR images. We included these 31 
cases in which the interpretation was 
not blinded to the other imaging results, 
but we also calculated results with these 
cases excluded and found no substan-
tive differences in the conclusions. The 
investigators had full knowledge of the 
conventional imaging and prestudy bi-
opsy results. In reviewing each image set 
(conventional, MR, and PEM), the inves-
tigator described the suspected overall 
extent and focality of the tumor and as-
certained whether or not the participant 
was likely to be a candidate for BCS. 
Integrated interpretation across all mo-
dalities was then performed at the sites 
by a study investigator to determine the 
overall extent of suspected disease. 
 Each presurgical and surgical pro-
cedure was documented, and the de-
tails of the histopathologic correlations 
are described in Appendix E1 (online). 
tied to outcomes. This author received 
a laptop computer from Medipattern 
(Toronto, Ontario, Canada) and has 
consulted as a reader for SuperSonic, 
Imagine (Aix, Provence, France). One 
author (D.N.) is a previous employee of 
and holds stock in Naviscan. Another 
author (J.E.K.) is a current employee 
of and holds stock options in Naviscan. 
An author (E.D.P.) who is neither an 
employee of nor consultant for Navis-
can had control of the inclusion of any 
data and information that might have 
represented a confl ict of interest for 
those authors who are or were em-
ployees of or consultants for Naviscan. 
The laboratory of this author receives 
research support from GE Medical 
Systems (Waukesha, Wis), Sectra NA 
(Shelton, Conn), Konica Minolta Medi-
cal Imaging USA (Wayne, NJ), and Ho-
logic (Bedford, Mass) and is negotiating 
a research contract with Naviscan. Two 
authors (K.S.M., J.P.M.) are employees 
of Certus International (St Louis, Mo), 
which served as the central research 
organization and was paid by Naviscan. 
The participating sites met the techni-
cal and experience requirements, and 
obtained institutional review board ap-
proval, to participate in this Health In-
surance Portability and Accountability 
Act–compliant study. Details regarding 
the study investigators, inclusion and 
exclusion criteria, imaging methods, 
data collection, and statistical analyses 
are given in Appendix E1 (online) and 
summarized here. 
 Participants 
 Women 25 years of age or older with 
newly diagnosed invasive and/or intra-
ductal breast cancer detected at core-
needle or vacuum-assisted biopsy (ie, 
an index cancer) were recruited from 
six sites and provided written informed 
consent. To be eligible, the women had 
to be candidates for BCS on the basis of 
the recommendation of a breast surgeon 
and the following criteria: The tumor 
was confi ned to one quadrant ( , 4 cm in 
largest overall extent at initial review of 
prestudy images) and was not believed to 
involve the skin or chest wall. In women 
with large breasts, a tumor size of up to 
5 cm was allowed. 
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 Performance in Detection of Known 
Malignancies 
 Among the 404 index malignancies in 
388 breasts, 386 index lesion sites in 
370 breasts were confi rmed with sur-
gery. PEM tended to better depict 
cancer when it was present, depict-
ing 357 (92.5%) of the 386 foci versus 
344 (89.1%) foci depicted with MR 
imaging ( P = .079, nonsignifi cant differ-
ence). Biopsy sites were more readily 
identifi ed with MR imaging ( Table 1 ). 
The absence of visible tumor or biopsy 
site changes on MR and PEM images in 
seven and 19 breasts, respectively, did 
not accurately predict the absence of 
residual tumor at surgery: All of these 
breasts were found to have residual tu-
mor at surgery. The documented rea-
sons that the known malignancy was not 
seen on the PEM images in 19 breasts 
were as follows: There was no increase 
in FDG uptake in 11 breasts, the ma-
lignancy was not included in the fi eld 
of view in six breasts, and unknown for 
two breasts. 
 Breast-Level Performance in Detection of 
Additional Tumor 
 Of 388 ipsilateral breasts, 82 (21%) were 
found to have additional foci of tumor 
after study entry. Of these 82 breasts, 
49 (60%; 95% confi dence interval [CI]: 
48%, 70%) were identifi ed with MR im-
aging; 42 (51%; 95% CI: 40%, 62%), 
with PEM ( P = .24); and 22 (27%; 95% 
CI: 18%, 38%), with conventional im-
aging review ( Table 2 ). An important 
result was the detection of additional 
disease with only MR imaging in 21 
(26%) of the 82 breasts with addition-
al tumor, with only PEM in 14 (17%) 
( P = .31) breasts, and with only conven-
tional imaging review in seven (8.5%). The 
addition of conventional imaging review 
to either MR imaging or PEM signifi -
cantly improved sensitivity compared 
with the sensitivity of MR imaging or 
PEM alone ( Table 2 ). Integrating the 
PEM and MR fi ndings signifi cantly im-
proved the detection of additional can-
cer: to 61 (74%) of 82 breasts versus 
49 (60%) of 82 breasts with MR imag-
ing alone ( P  , .001). Twelve women 
(3.1% of all 388 participants, 15% of 
82 participants with additional tumor) 
 6 0.8 (standard deviation) (range, 
7.6–12.8 mCi [281.2–473.6 MBq]); the 
mean blood glucose level, 91 mg/dL 
 6 15 (range, 51–148 mg/dL); and the 
mean circulation time, 69 minutes  6 14 
(range, 44–155 minutes). The demo-
graphics of the subjects who completed 
the protocol (ie, participants) did not 
differ markedly from those of the women 
who did not complete the protocol, with 
the exceptions that the study participants 
were less likely to have known meta-
static axillary nodes, had a smaller me-
dian invasive tumor size, were less likely 
to have multiple known malignancies, 
and were more likely to have recently 
taken hormone replacement medication 
(Table E1 [online]). 
 With the most severe diagnosis at 
study entry per participant considered 
the index malignancy, 84 (21.6%) of the 
388 index cancers were ductal carcinoma 
in situ (DCIS), 302 (77.8%) were in-
vasive cancers, one was Paget disease 
of the nipple, and one was pleomorphic 
lobular carcinoma in situ being treated 
as a malignancy. Of the 388 participants, 
372 (95.9%) had known solitary malig-
nancy at study entry; 14 (3.6%), known 
multifocal tumor; and two (0.5%), 
known multicentric tumor (believed to 
be candidates for double lumpectomy), 
yielding a total of 404 ipsilateral index 
cancers. No participants were known to 
have bilateral cancer. 
 After all treatment surgeries had 
been performed, 283 (72.9%) of the 
388 ipsilateral breasts had a solitary 
tumor; 66 (17.0%), multifocal disease; 
21 (5.4%), multicentric disease; 11 (2.8%), 
both multifocal and multicentric tumors; 
three (0.8%), multiple separate cancers 
that could not be further classifi ed; and 
four (1.0%), diffuse tumor throughout 
the breast. Forty-fi ve (12%) breasts had 
an extensive intraductal component. 
Seventy-fi ve (19%) breasts had pure 
DCIS, and 311 had invasive tumor, with 
an overall median invasive tumor size 
of 1.5 cm (range, 0.1–8.0 cm). The 
median time to initial surgery for the 
participants with no additional suspi-
cious fi ndings at imaging was 15 days 
(range, 2–100 days) compared with 
22 days (range, 5–76 days) for those 
with suspicious fi ndings. 
biopsy specimen. Negative truth was 
defi ned as a diagnosis of benign lesion 
or high-risk lesion on the basis of the 
most severe fi nding at histopathologic 
analysis, or a probably benign lesion 
that decreased in size or resolved at 
any follow-up. For lesions initially con-
sidered probably benign, the absence of 
cancer after biopsy or the absence of 
a suspicious change after a minimum of 
6 months of imaging follow-up (median 
follow-up, 10.5 months; range, 6.1–19.2 
months) was considered negative truth. 
Similarly, an integrated interpretation 
of BI-RADS 2 across all modalities or 
BI-RADS 1 or 2 after additional imaging 
was considered negative truth. 
 At the breast level, if any additional 
malignancy was present and was true-
positive at imaging, the breast was consid-
ered to have true-positive fi ndings, even 
if another lesion in that breast was false-
negative or false-positive. A breast with 
both false-positive and false-negative 
lesions was classifi ed as a false-negative 
case at the breast level. An additional 
description of the statistical analyses is 
given in Appendix E1 (online). Diagnostic 
performance characteristics, including 
sensitivity, specifi city, accuracy, PPV, and 
area under the receiver operating char-
acteristic curve, were estimated and com-
pared for each imaging modality and for 
integrated imaging assessments.  P  , .05 
was considered to indicate statistical 
signifi cance. 
 Results 
 A total of 388 eligible women (mean 
age, 57.8 years; median age, 58 years; 
age range, 26–93 years), each of whom 
had one breast with newly diagnosed 
cancer (Fig E1 [online]), completed the 
study protocol. The median estimated 
invasive tumor size at study entry was 
1.5 cm (range, 0.4–6.9 cm). The me-
dian time from routine-view mammog-
raphy to the fi rst study imaging exami-
nation was 30 days (standard deviation, 
21 days; range, 0–121 days). Of the 
388 participants, 271 (70%) underwent 
digital mammography and 117 (30%) 
underwent screen-fi lm mammography 
prior to study entry. The mean injected 
dose of FDG was 10.9 mCi (403.3 MBq) 
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different when the eight probably benign 
lesions that were not followed up were 
excluded or when they were considered 
malignant (Table E2 [online]). Lesion-
level accuracy was similar across the mo-
dalities: 60.7% (185 of 305 lesions) for 
MR imaging, 64.9% (198 of 305 lesions) 
for PEM ( P = .25), and 66.2% (202 of 
305 lesions) for conventional imaging 
( P = .14 for comparison with MR imaging). 
The PPVs of biopsies prompted by PEM 
fi ndings (66% [47 of 71 lesions]) ( P = .016) 
or by conventional imaging review (69% 
[24 of 35 lesions]) ( P = .041) were high-
er than the PPV of biopsies prompted by 
MR fi ndings (53% [61 of 116 lesions]). 
The PPV of biopsy was higher with 
combined PEM and conventional imag-
ing (65% [60 of 92 lesions]) than with 
combined MR and conventional imag-
ing (54% [73 of 136 lesions]) ( P = .009) 
( Table 4 ). Lesions that were suspicious 
on both PEM and MR images (30/40 
[75%]) were more likely to be malignant 
than were lesions that were suspicious on 
MR images only (31/76 [41%]) ( P   .001). 
 MR imaging was less sensitive for 
detection of DCIS foci (39% [22/56]) 
than for detection of any invasive can-
cer (64% [38/59]) ( P = .007) ( Table 5 ), 
although no difference based on tumor 
type was seen with PEM. The addition 
of PEM to MR imaging significantly 
improved the detection of DCIS, from 
22 (39%) of 56 lesions with MR imag-
ing alone to 32 (57%) lesions ( P = .001), 
and another seven DCIS foci were seen 
only at conventional imaging review, for 
an overall sensitivity of combined con-
ventional imaging, PEM, and MR im-
aging of 70% for the detection of DCIS. 
MR imaging was more sensitive for 
detection of invasive cancer than was 
PEM: Of 37 IDC lesions with or with-
out DCIS, 21 (57%) were seen at MR 
imaging compared with 12 (32%) that 
were seen at PEM ( P = .02). The ad-
dition of PEM to MR imaging improved 
the detection of invasive cancer, from 
38 (64%) of 59 lesions depicted with 
MR imaging alone to 43 (73%) lesions 
( P = .025). Two high-grade IDC foci with 
or without DCIS were seen only at con-
ventional image review. 
 There was no signifi cant effect of inves-
tigative site, hormone use, or menopausal 
invasive ductal carcinoma (IDC) with or 
without DCIS, three (3%) were com-
bined IDC–invasive lobular carcinoma 
with or without DCIS, 19 (16%) were in-
vasive lobular carcinoma with or without 
DCIS, and one (1%) was a metastatic in-
tramammary node. These additional tu-
mor foci had a median size of 0.7 cm (stan-
dard deviation, 1.7; range, 0.1–7.3 cm); 
the nearly purely invasive tumor foci 
(with  , 10% DCIS) had a median size of 
0.6 cm (standard deviation, 1.8; range, 
0.1–7.3 cm). 
 Of the 116 malignant lesions that 
were not known at study entry, 61 (53%; 
95% CI: 43%, 62%) were reported as 
suspicious at MR imaging; this was more 
than the 47 (41%; 95% CI: 32%, 50%) 
malignant lesions reported as suspicious 
at PEM ( P = .04) and much more than 
the 24 (21%; 95% CI: 14%, 29%) le-
sions reported as suspicious at conven-
tional imaging review ( P  , .001). PEM 
was also much more sensitive than con-
ventional imaging ( P  , .001) ( Table 4 ). 
For characterization of the 189 benign 
lesions, PEM was more specifi c than MR 
imaging, with 151 (79.9%) of these le-
sions imaging negative on PEM images 
compared with 124 (65.6%) imaging 
negative on MR images ( P = .002), but it 
was less specifi c than conventional imag-
ing, where 178 (94.2%) of these lesions 
were imaging negative ( P  , .001). Results 
at the lesion level were not signifi cantly 
had additional tumor foci in the ipsilat-
eral breast that was not identifi ed with 
any imaging modality: Eight breasts had 
10 invasive lesions with a median size 
of 0.3 cm (range, 0.1–1.0 cm), and four 
breasts had DCIS. At evaluation of the 
306 breasts without additional cancer, 
PEM was signifi cantly more specifi c than 
MR imaging (91.2% versus 86.3%, 
 P = .032) and similar in performance to 
conventional imaging ( Table 2 ). Accuracy 
at the breast level was similar across 
modalities at 80.7%–82.7%. The area 
under the receiver operating charac-
teristic curve was 0.76 for MR imaging 
(95% CI: 0.70, 0.82) and 0.72 for PEM 
(95% CI: 0.66, 0.78) ( P = .37). 
 Lesion-Level Performance in Detection of 
Additional Tumor 
 Fifty (13%) of the 388 women underwent 
59 ipsilateral presurgical percutaneous 
core-needle biopsies after study entry, 
with 26 (44%) of these procedures yield-
ing malignancies ( Table 3 ). A total of 
305 discrete nonindex ipsilateral lesions 
were identifi ed: 211 of these lesions 
underwent biopsy or direct excision, 
including 116 malignancies, 14 high-risk 
lesions (fi ve at core-needle biopsy, all 
excised with no upgrades), and 81 be-
nign lesions. Follow-up imaging fi ndings 
showed the remaining 94 lesions to be 
benign. Of the 116 additional malignant 
foci, 56 (48%) were DCIS, 37 (32%) were 
 Table 1 
 Results for 388 Breasts with 404 Sites of Known Malignancy 
Parameter PEM MR Imaging  P Value
Sensitivity
 Tumor seen 357/386 (92.5) 344/386 (89.1) .079
 Tumor or biopsy site seen 365/386 (94.5) 379/386 (98.2) .004
Specifi city
 Tumor seen 2/18 (11) 13/18 (72) .001
 Tumor or biopsy site seen 0/18 (0) 0/18 (0) NA * 
Accuracy
 Tumor seen 360/404 (89.1) 357/404 (88.4) .71
 Tumor or biopsy site seen 366/404 (90.6) 379/404 (93.8) .006
Note.—Sensitivity data are based on 386 index lesion sites with residual malignancy confirmed at surgery. Investigators 
documented that the known (index) malignancy was seen at imaging, that only the biopsy site changes were seen, or that 
nothing was seen at the site of known tumor. Results were calculated by considering only the tumor to be seen as positive for 
cancer as well as by considering the tumor or biopsy site to be seen as positive. Specifi city data are based on the 18 sites found 
to have no residual tumor at surgery. Accuracy data are based on the 404 original lesion sites (386 with residual cancer plus 18 
without residual cancer at surgery). Numbers in parentheses are percentages.
* NA = not applicable.
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 Table 2 
 Breast-Level Performance of Conventional Imaging, PEM, MR Imaging, and Combined Modalities 
 Modality and Comparison
Sensitivity * Specifi city * Accuracy * 
AUC † Value 95% CI Value 95% CI Value 95% CI
Conventional imaging review 22/82 (27) 18, 38 298/306 (97.4) 94.7, 98.7 320/388 (82.5) 78.2, 86.0 0.63 (0.57, 0.68)
MR Imaging 49/82 (60) 48, 70 264/306 (86.3) 81.8, 89.8 313/388 (80.7) 76.3, 84.4 0.76 (0.70, 0.82)
PEM 42/82 (51) 40, 62 279/306 (91.2) 87.3, 93.9 321/388 (82.7) 78.5, 86.3 0.72 (0.66, 0.78)
 P value, PEM vs MR .24 … .032 .38 … .37
PEM + MR ‡ 61/82 (74) 63, 83 255/306 (83.3) 78.6, 87.2 316/388 (81.4) 77.1, 85.1 0.84 (0.79, 0.90)
 P value, (PEM + MR) vs 
  MR alone
 , .001 … .02 … .56 …  , .001
PEM + MR + conventional 
  imaging ‡ 
68/82 (83) 73, 90 252/306 (82.4) 77.5, 86.3 320/388 (82.5) 78.2, 86.0 0.87 (0.82, 0.92)
 P value, (PEM + MR + 
   conventional imaging) vs MR 
alone 
 , .001 … .004 … .25 …  , .001
MR + conventional imaging ‡ 59/82 (72) 61, 81 259/306 (84.6) 80.0, 88.3 318/388 (82.0) 77.7, 85.5 0.80 (0.74, 0.86)
 P value, (MR + conventional 
  imaging) vs MR alone
.001 … .025 … .20 … .021
PEM + conventional imaging ‡ 53/82 (65) 53, 74 275/306 (89.9) 85.8, 92.8 328/388 (84.5) 80.5, 87.9 0.79 (0.73, 0.85)
 P  value, (PEM + conventional 
  imaging) vs PEM alone
 , .001 … .045 … .070 … .002
 P  value, (PEM + conventional 
   imaging) vs (MR + conventional 
imaging)
.26 … .018 … .25 … .79
Note.—Data are values of breast-level performance for conventional Imaging, PEM, MR imaging, and combined imaging modalities for 82 breasts with additional ipsilateral malignancies among 388 
participants with newly diagnosed breast cancer.
* Values are numbers of ipsilateral breasts, with percentages in parentheses. Ninety-fi ve percent CIs for percentages are also given.
 † AUC = area under receiver operating characteristic curve. Numbers in parentheses are 95% CIs.
 ‡ Integrated interpretation across modalities. Integrated interpretations could be upgraded or downgraded compared with individual modality interpretations.
 Table 3 
 PPVs of Additional Ipsilateral Biopsies among 388 Women with Newly Diagnosed Breast Cancer 
Type of Biopsy All Lesions
Lesions at Conventional 
Imaging Only * Lesions at MR Only * Lesions at PEM Only * Lesions at MR and PEM * 
Lesions Not Prompted 
by Imaging Findings † 
Core-needle ‡§ 26/59 (44) 4/6 (67) 11/30 (37) 2/6 (33) 9/12 (75) 0/5
Needle-localized 
  excision
0/3 (0) 0/1 (0) 0/1 (0) 0/1 (0) 0 0
Direct excision 90/149 (60) 5/8 (63) 20/45 (44) 15/24 (63) 21/28 (75) 29/44 (66)
 Total 116/211 (55 [48.0, 61.7]) 9/15 (60 [33, 80]) 31/76 (41 [30, 52]) § 17/31 (55 [36, 71) 30/40 (75 [58, 86]) 29/49 (59 [44, 72]) § 
Note.—Data are numbers of malignant lesions found at biopsy/total number of lesions biopsy. Numbers in parentheses are percentages. In Total row, numbers in brackets are 95% CIs for 
percentages.
* Lesions considered suspicious (ie, imaging positive, BI-RADS 4a or higher, or BI-RADS 3 with recommendation for biopsy) at review of conventional images only, MR images only, PEM images only, 
or both MR and PEM images. The lesions suspicious on both conventional and MR images are included among the MR lesions, and the lesions suspicious on both conventional and PEM images are 
included among the PEM lesions.
 † Biopsy may have been recommended at additional imaging performed after the breast lesion was assigned a score of BI-RADS 3 or lower, a lesion assigned a score of BI-RADS 3 or lower was included 
in the excised tissue, or the lesion was not identifi ed until surgery.
 ‡ Included vacuum-assisted biopsy.
 § Core-needle procedures included two fi ne-needle aspiration biopsies that yielded benign fi ndings: one prompted by MR fi ndings and one performed only after additional imaging.
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status on the sensitivity or specifi city 
of PEM or MR imaging. MR imaging 
tended to be more sensitive than PEM 
in small breasts (brassiere cup size 
A or B), depicting 23 (58%) of 40 tumor 
foci compared with 14 (35%) depicted 
by PEM ( P = .066, not signifi cant). 
MR imaging was more sensitive than 
PEM in dense breasts (sensitivity, 57% 
[34/60] vs 37% [22/60] with PEM; 
 P = .031). The rate of additional can-
cer detection was similar for all breast 
density categories, with the exception 
that no additional cancers were found 
in fatty breasts. The sensitivities of MR 
imaging and PEM were also analyzed 
according to invasive tumor size for the 
40 additional nearly purely invasive le-
sions: Of 16 1–5-mm T1a lesions, fi ve 
(31%) were depicted by MR imaging 
and four (25%) were depicted by PEM 
( P  . .99). Of 13 6–10-mm T1b lesions, 
12 (92%) were depicted by MR imaging 
and six (46%) were depicted by PEM 
( P = .041). All fi ve (100%) 11–20-mm 
T1c lesions were depicted by MR imag-
ing, and three (60%) were depicted by 
PEM ( P = .48). The sensitivity of PEM 
improved with increasing lesion size 
( P = .021). The sensitivity of MR imag-
ing tended to improve with increasing 
lesion size ( P = .058) 
 Surgical Management 
 Of 388 study participants, 56 (14%) ulti-
mately required mastectomy on the basis 
of the extent of disease ( Figure , Fig E2 
[online]). Of these 56 women in whom 
mastectomy was necessary, 40 (71%) 
were correctly identifi ed with MR imag-
ing (22 of whom were identifi ed only by 
MR imaging); 20 (36%) were correctly 
identifi ed with PEM ( Table 6 ) ( P  , .001), 
18 were correctly identifi ed with both 
MR imaging and PEM, and two were 
correctly identifi ed with PEM only. The 
disease extent was underestimated on all 
imaging in 14 participants who eventu-
ally underwent appropriate mastectomy, 
eight (57%) of whom had an extensive 
intraductal component. Eleven (2.8% of 
all participants) women underwent inap-
propriate mastectomy that was prompted 
by imaging: fi ve cases prompted by MR 
fi ndings only, one prompted by PEM 
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PEM and MR imaging were more likely 
to lead to an underestimation of disease 
extent when an extensive intraductal 
component was present than when it 
was not (for comparison of accuracy be-
tween breasts with and those without ex-
tensive intraductal component:  P = .004 
for PEM accuracy,  P = .012 for MR accu-
racy), although MR imaging performed 
slightly better than PEM in such cases 
( Table 8 ). Cancer-positive margins were 
much more common in breasts with 
an extensive intraductal component: 
13 (37%) of 35 women with an exten-
sive intraductal component in whom 
BCS was attempted had positive mar-
gins at initial surgery compared with 
30 (11%) of 278 women who had posi-
tive margins without an extensive intra-
ductal component ( P  , .001). 
 Other factors that increased the 
like lihood of mastectomy were positive 
262 (67%) ipsilateral breasts, under-
estimated in 85 (22%) breasts, and 
overestimated in 41 (11%) ( P  , .001 
that MR imaging was more accurate). 
In 28 (7.2%) breasts, PEM was more 
accurate in depicting the extent of dis-
ease than was MR imaging, and in 39 
(10%) breasts, MR imaging was more 
accurate than was PEM ( P = .22, not 
signifi cant). The two examinations 
were equally likely to lead to overesti-
mation of disease, but MR imaging was 
less likely to lead to underestimation of 
disease than was PEM. 
 Several factors increased the need 
for mastectomy. When an extensive in-
traductal component was present, mas-
tectomy was required for 16 (36%) of 
45 breasts, compared with 40 (12%) of 
343 breasts requiring mastectomy when 
an extensive intraductal component was 
not present ( P  , .001) ( Table 7 ). Both 
 For 54 (14%) of the 388 women, 
the local excision was wider than that 
planned at conventional imaging, and 
the wider excision was deemed to be 
appropriate in 33 of these cases ( Table 6 ). 
Another 20 cases were considered to 
have had unnecessarily wider local ex-
cision prompted by imaging: Nine were 
prompted by MR imaging only; six, by 
PEM only; and fi ve, by both. One high-
risk lesion (lobular carcinoma in situ 
and atypical ductal hyperplasia) was 
suspicious on both PEM and MR imag-
ing, prompting wider local excision. 
 MR imaging was more accurate than 
PEM in surgical planning. MR imaging 
was accurate for 292 (75%) of the 388 
ipsilateral breasts, led to an underesti-
mation of disease in 47 (12%) breasts, 
and led to an overestimation of disease 
in 49 (13%). The disease extent deter-
mined by using PEM was accurate for 
 Table 5 
 MR, PEM, and Combined PEM-MR Detection Rates as Functions of Histopathologic Results for 211 Lesions Undergoing 
Biopsy after Study Entry 
Histopathologic Finding * No. of Lesions MR Detection Rate † PEM Detection Rate †  P  Value, MR vs PEM PEM + MR Detection Rate †‡ 
 P  Value, (PEM + MR) 
vs MR Alone 
Malignant 116 61 (53) 47 (41) .04 76 (66)  , .001
 DCIS 56 22 (39) 23 (41) .83 32 (57) .001
  Low nuclear grade 5 2 (40) 1 (20) 2 (40)
  Intermediate nuclear grade 21 10 (48) 12 (57) 15 (71)
  High nuclear grade 30 10 (33) 10 (33) 15 (50)
 IDC with or without DCIS 37 21 (57) 12 (32) .02 24 (65) .08
  Grade I 13 6 (46) 3 (23) 7 (54)
  Grade II 14 9 (64) 5 (36) 10 (71)
  Grade III 10 6 (60) 4 (40) 7 (70)
 IDC-ILC with or without DCIS 3 3 (100) 2 (67) NA 3 (100) NA
 ILC with or without DCIS 19 14 (74) 10 (53) .16 16 (84) .16
 All invasive 59 38 (64) 24 (41) .004 43 (73) .025
 Metastatic intramammary node 1 1 (100) 0 NA 1 (100) NA
High risk § 14 11 (79) 5 (36) .033 12 (86) .32
Benign || 81 .016  , .001
 Imaging positive 44 (54) 19 (23) 47 (58)
 Imaging negative 4 (5.0) 10 (12) 22 (27)
All lesions 211 122 (57.8) 82 (39)  , .001 161 (76.3)  , .001
Note.—Data are imaging detection rates as functions of histopathologic analysis for 211 lesions that underwent biopsy after study entry. NA = not applicable because there were too few entries for 
 P value comparison.
* ILC = invasive lobular carcinoma.
 † Data are numbers of lesions, with percentages in parentheses.
 ‡ Integrated assessment of PEM and MR fi ndings, with exclusion of lesions seen only on conventional images.
 § High-risk lesions were seven atypical ductal hyperplasia lesions, four lobular carcinoma in situ lesions, two atypical lobular hyperplasia lesions, and one radial scar–complex sclerosing lesion.
 || Benign lesions found to be positive at any imaging modality were 19 fi brocystic changes, eight fi broadenomas, fi ve lymph nodes, one papilloma, and one ruptured cyst. Details on 13 benign lesions 
were not available.
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 Images obtained in 68-year-old woman who previously underwent right mastectomy for cancer and was noted to have lump in left breast. 
 (a) Lump was shown to correspond to 2.8-cm indistinctly marginated mass (triangular marker) on craniocaudal mammogram. US-guided 
core-needle biopsy revealed grade III IDC.  (b) Craniocaudal and  (c) mediolateral oblique PEM images (5.6-mm section thickness) obtained 
beginning 70 minutes after intravenous injection of 10.4 mCi (384.8 MBq) of FDG show intense rim uptake in known cancer (curved arrows). 
Approximately 5 cm medial and inferior to this region, intense FDG uptake was noted in second, 1-cm mass (straight arrow).  (d) Axial maximum 
intensity projection of left breast subtraction of precontrast images from three-dimensional spoiled gradient-echo T1-weighted MR images 
obtained 90 seconds after intravenous injection of 0.1 mmol of gadoversetamide (OptiMARK; Mallinckrodt, St Louis, Mo) per kilogram of body 
weight also shows rim enhancement in known malignancy (curved arrows) and intense enhancement in second, 1-cm mass (long straight arrow) 
in lower inner region of breast. Metastatic axillary nodes were suspected at MR imaging. The patient opted for direct mastectomy; histopathologic 
analysis confi rmed multicentric grade III IDC, the largest of which was 3.0 cm. The second mass was confi rmed to be 1.2-cm grade III IDC with 
a less than 5% DCIS component. A third 0.7-cm grade III IDC (straight short arrow) noted in the immediate retroareolar region was diffi cult to 
distinguish from normal nipple enhancement but visible on both PEM and MR images. Two of fi ve sentinel nodes showed metastatic disease. 
Both PEM and MR imaging correctly depicted multicentric disease that was not seen at mammography. 
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margins at initial excision or recom-
mendation for mastectomy based on 
PEM or MR fi ndings ( Table 7 ). Among 
the 388 participants, mastectomy was 
also more likely to be needed in 66 
(17%) cases with multifocal disease 
( P = .004 for comparison with unifo-
cal disease) and in 39 (10%) cases with 
multicentric disease than in the cases 
of solitary tumor ( P  , .001) ( Table 7 ). 
With MR imaging, the disease extent of 
13 (33%) of 39 multicentric tumors was 
less likely underestimated compared 
with 24 (62%) multicentric tumors whose 
disease extent was underestimated with 
PEM ( P = .015) ( Table 8 ). 
 In 283 breasts with a solitary tu-
mor, the tumor size was more often ac-
curately determined with MR imaging 
(223 [78.8%] breasts) than with PEM 
(210 [74.6%] breasts) ( P = .005), be-
ing underestimated by 2 cm or more 
in 20 (7.1%) breasts with MR imaging 
and in 36 (13%) breasts with PEM. Ini-
tial margins were positive for cancer in 
25 (10%) of 245 breasts with solitary 
tumors for which BCS was attempted 
initially versus in 11 (22%) of 51 breasts 
with multifocal tumor ( P = .042) and 
seven (41%) of 17 breasts with multi-
centric tumor ( P  , .001 for comparison 
with solitary tumor) ( Table 8 ) for which 
BCS was attempted initially. Of the sub-
set of 176 solitary invasive cancers with 
a lower than 10% in situ component, 
166 were seen on PEM images; 163, on 
MR images; and 153, on both. Pearson 
correlation coeffi cients between tumor 
size at imaging and at histopathologic 
analysis for the 153 tumors seen on MR 
and PEM images were 0.55 for PEM 
and 0.81 for MR imaging ( P  , .001 for 
greater accuracy of MR imaging). 
 Discussion 
 In this prospective trial, we found that 
among 388 women anticipating BCS, ad-
ditional tumor was depicted by MR im-
aging in 13% ( n = 49) of them, by PEM 
in 11% ( n = 42), and with conventional 
imaging review in 5.7% ( n = 22). Our 
MR imaging results are similar to the 
16% rate of detecting additional foci in a 
meta-analysis involving 2610 women with 
newly diagnosed cancer ( 5 ). We found 
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characterized as imaging negative) and 
less likely to prompt unnecessary biop-
sies. At the lesion level, PEM was less 
sensitive than MR imaging (47 [41%] 
compared with 61 [53%] of 116 malig-
nant lesions imaging positive), although 
there was no difference in sensitivity at 
the participant level. Furthermore, PEM 
proved to be complementary to MR im-
aging, increasing the additional ipsilateral 
cancer detection rate from 49 (60%) to 
61 (74%) of 82 participants with addi-
tional cancer and depicting additional 
ipsilateral malignancies that were not 
seen on MR images in 14 (3.6%) of the 
388 participants. 
 We found that conventional image 
review signifi cantly improved the de-
tection of additional malignancies, with 
additional ipsilateral tumor foci (all DCIS) 
in seven participants (1.8%) seen only 
at conventional image review. Our re-
sults suggest that a coordinated review 
of all breast imaging studies at the time 
of PEM or MR image interpretation is 
important for improved diagnosis. Even 
after the combination of conventional 
imaging review, PEM, and MR imaging, 
additional ipsilateral foci remained un-
detected in 12 (15%) of the 82 women 
with additional tumors (3.1% of all the 
women examined), suggesting that there 
is room for further improvement. This 
emphasizes the need for caution when 
making decisions about adjuvant radia-
tion therapy, especially partial breast 
irradiation, in women with negative im-
aging results. 
 The use of MR imaging for preop-
erative evaluation is under close scrutiny 
owing to resulting increased rates of 
mastectomy (10,12–14) and treatment 
delays, which averaged 22 days in one 
series ( 10 ), particularly in the absence 
of decreased rates of repeat surgery 
( 10,15 ), decreased recurrences ( 16,17 ), 
or improved survival ( 16,17 ). False-
positive results of biopsies prompted by 
MR fi ndings result in extra testing and 
stress for the patient, add to costs, and 
delay treatment. Our reported PPVs of 
53% for biopsies prompted by MR im-
aging and 69% for conventional imaging 
were within expected ranges for breasts 
ipsilateral to malignancy ( 5,18 ). The 
PPV of 66% for biopsies prompted by 
 We found that PEM was more spe-
cifi c than MR imaging at the lesion 
level (151 [79.9%] compared with 124 
[65.6%] of 189 benign lesions correctly 
additional unsuspected ipsilateral tumor 
foci, and MR imaging missed additional 
foci in 40% (33 of 82) of these women, 
or 8.5% of all the participants. 
 Table 7 
 Comparison of 56 Breasts Appropriately Treated with Ipsilateral Mastectomy on the 
Basis of Disease Extent with 332 Ipsilateral Breasts Needing Only Lumpectomy 
Parameter * No. of Breasts
Mastectomy 
Appropriate 
( n = 56)
Lumpectomy 
Would Have 
Suffi ced ( n = 332)  P Value
Median age (y) † … 54 (29–84) 58 (26–93) .062
Histopathologic tumor type .17
 DCIS 75 (19) ‡ 9 (12) 66 (88)
 IDC with or without DCIS 256 (66.0) 34 (13) 222 (86.7)
 IDC-ILC with or without DCIS 24 (6.0) 4 (17) 20 (83)
 ILC with or without DCIS § 31 (8.0) 8 (26) 23 (74)
 Other || 2 (0.5) 1 (50) 1 (50)
Extensive intraductal 
  component present
 , .001
 Yes 45 (12) 16 (36) 29 (64)
 No 343 (88.4) 40 (12) 303 (88.3)
Tumor size  , .001
 Invasive cancer 313 (80.7) 2.0 (0.3–8.0) ‡# 1.4 (0.1–6.0) # 
 Pure DCIS 75 (19) 6.0 (1.0–8.8) ‡# 1.0 (0.2–5.8) # 
Tumor focality  , .001
 Single tumor 283 (72.9) 17 (6) 266 (94.0)
 Multifocal 66 (17) 11 (17) 55 (83)
 Multicentric, diffuse ** 39 (10) 28 (72) 11 (11)
Initial Margin Status .008
 Negative 301 (77.6) 35 (12) 266 (88.4)
 Positive 46 (12) 14 (30) 32 (70)
 Close 41 (11) 7 (17) 34 (83)
No. of surgeries .011
 One 316 (81.4) 38 (12) 278 (88.0)
 Multiple †† 72 (19) 18 (25) 54 (75)
Need for mastectomy predicted 
  on basis of PEM fi ndings
 , .001
 Yes 28 (7.2) 17 (61) 11 (39)
 No 360 (92.8) 39 (11) 321 (89.1)
Need for mastectomy predicted
  on basis of MR fi ndings
 , .001
 Yes 57 (15) 39 (68) 18 (32)
 No 331 (85.3) 17 (5) 314 (94.9)
Note.—Data are summarized for 56 breasts appropriately treated with ipsilateral mastectomy on the basis of disease extent 
compared with 332 breasts that did not require mastectomy, among 388 study participants. Unless otherwise noted, data are 
numbers of breasts, with percentages in parentheses.
* ILC = invasive lobular carcinoma.
 † Numbers in parentheses are age ranges.
 ‡ Forty-seven invasive tumors with or without DCIS required mastectomy, as did nine participants with pure DCIS.
 §  P = .076 for rate of mastectomy for ILC versus rate of mastectomy for other tumor types.
 || Other includes one case of invasive tubulobular carcinoma and one case of sarcoma arising in phyllodes tumor.
 # Median tumor size, in centimeters, with range in parentheses.
** Includes multiple tumors that could not be further classifi ed.
 †† Three hundred sixteen participants underwent a single surgery; 59, two surgeries; 10, three surgeries; two, four surgeries; 
and one, more than four surgeries for treatment of ipsilateral breast cancer.
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PEM was slightly lower than previously 
reported values ( 11 ) but signifi cantly 
higher than the PPV of MR imaging. Nev-
ertheless, if additional sus picious fi nd-
ings are identifi ed, presurgical biopsy 
should be performed to confi rm the need 
for wider excision or mastectomy. An im-
portant result was the signifi cantly im-
proved specifi city of PEM (91.2%) com-
pared with the specifi city of MR imaging 
(86.3%) ( P = .032), with six unnecessary 
mastectomies prompted by PEM and 10 
prompted by MR imaging ( P = .45, not 
signifi cantly different). In our series, we 
observed a median 7-day delay in the 
time to surgery for participants with 
suspicious fi ndings at imaging compared 
with those with no suspicious fi ndings. 
 Several factors may have contrib-
uted to the reduced sensitivity of PEM 
in our series. In our study, if the index 
malignancies had been included, the 
overall sensitivity of PEM would have 
been 80.5% (404 of all 502 malignant 
lesions vs the observed 41% [47 of 116 
lesions] we report herein for the detec-
tion of unknown malignancies), which 
is nearly identical to the 80.7% (405 of 
502 lesions) sensitivity for the detection 
of combined index and unknown ma-
lignancies with MR imaging ( P = .92). 
Avril et al ( 19 ) found that the sensitivity 
of whole-body FDG PET was highly de-
pendent on the size of the breast cancer, 
with only three (25%) of 12 cancers 1 cm 
or smaller identifi ed compared with 
greater than 90% sensitivity for the de-
tection of tumors 2 cm or larger. We 
found PEM sensitivity increased with in-
creasing size of malignancy in this series. 
The section thickness of PEM images 
increases with increasing breast thick-
ness, as 12 sections are always gener-
ated with PEM: Section thickness varied 
from 3 to 8 mm in our current series. 
As such, the sensitivity of PEM for the 
detection of smaller lesions may be re-
duced in larger breasts owing to volume 
averaging. PEM-guided percutaneous 
biopsy ( 20 ) became available late in this 
protocol and at only two sites. This may 
have discouraged investigators from call-
ing small or vague malignant foci positive 
at PEM. While posterior lesions can be 
seen, there is some loss of linearity up 
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